JS Link
Financials
Valuation Metrics
JS Link's Market Cap is ₩7952B. At end of 2025 it was ₩6680B. Ranked #333 of 2,414 in KR market (top 14%), #95 of 1,633 on KOSDAQ (top 6%), #36 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 16%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 795.20B KRW | KR#333/2,414 Sec#36/231 |
| Revenue | 22.78B KRW | KR#2,107/2,414 Sec#153/231 |
| Net Income | -5.30B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 187.70B KRW | KR#1,357/2,414 Sec#99/231 |
| Net Assets | 103.50B KRW | KR#1,390/2,414 Sec#109/231 |
| Employees | 80 | KR#1,807/2,414 Sec#152/231 |
| Value | ||
| P/B | 7.68x | KR#2,335/2,414 Sec#206/231 |
| P/S | 34.91x | KR#2,361/2,414 Sec#195/231 |
| FCF Yield | -6.72% | KR—/2,414 Sec—/231 |
| Profitability | ||
| ROE | -5.12% | KR#1,804/2,414 Sec#130/231 |
| ROA | -2.82% | KR#1,820/2,414 Sec#128/231 |
| Op. Margin | -63.17% | KR#2,249/2,414 Sec#162/231 |
| Revenue Growth | 51.26% | KR#201/2,414 Sec#27/231 |
| Financial Health | ||
| Debt Ratio | 81.35% | KR#1,365/2,414 Sec#159/231 |
| Total Debt | 54.14B KRW | KR#976/2,414 Sec#66/231 |
| FCF | -53.44B KRW | KR#2,086/2,414 Sec#206/231 |
| Cash | 72.23B KRW | KR#592/2,414 Sec#31/231 |
| Current Ratio | 1.55x | KR#1,159/2,414 Sec#127/231 |
| Performance | ||
| 1Y Return | -2.07% | KR#667/2,414 Sec#37/231 |
| 1M Return | -29.98% | KR#2,329/2,414 Sec#222/231 |
| From 52W High | -57.41% | KR#1,601/2,414 Sec#134/231 |
| 1Y MDD | -56.54% | KR#1,281/2,414 Sec#105/231 |
| Trading | ||
| Volume | 280,060 shares | KR#440/2,414 Sec#39/231 |
| Trading Value | 6.03B KRW | KR#349/2,414 Sec#29/231 |
| Foreign Own. | 3.41% | KR#1,173/2,414 Sec#107/231 |
| Per Share | ||
| EPS | -142 KRW | KR—/2,414 Sec—/231 |
| BPS | 2,766 KRW | KR#1,916/2,414 Sec#147/231 |
Company Info
Established in 2000 as a personalized medicine specialized healthcare company, the company will change its name to JS Link in 2025. It operates genome analysis technology-based services and molecular diagnostics businesses. Through an amendment to its articles of incorporation, JS Link is expanding into the production of permanent sintered magnets for future industries like electric vehicles and robots. The company is preparing for manufacturing by securing rare earth procurement partnerships, talent, and facility investments, while pursuing innovation in its technology platform. JS Link is headquartered in Gangseo-gu, Seoul Metropolitan City.